Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorization for Awiqli for treatment of diabetes in adults. Novo expects to receive final marketing authorization from the European Commission within approximately two months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk price target raised to DKK 900 from DKK 850 at Berenberg
- Novo Nordisk Advances Share Buyback Program
- Oprah to host TV special discussing weight loss, CNN reports
- Eli Lilly’s (NYSE:LLY) Weight-Loss Drug Outshines Wegovy for First Time
- Piper Sandler healthcare/pharma analysts hold analyst/industry conference call
